The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RGIN | +0% | -99.17% | -61.61% | -100% |
| S&P | +13.95% | +78.35% | +12.25% | +525% |
Regenicin, Inc. is a biotechnology company, which specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. It intends to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures. The company was founded on September 6, 2007 and is headquartered in Little Falls, NJ.
No news articles found for Regenicin.
No data available for this period.
Currently no data to display
Currently no data to display.
Currently no data to display.
No data available for this period.
No data available for this period.
No data available for this period.
No data available for this period.
| Metric | YoY Change |
|---|
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
